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osting by EAbstract Pantoprazole sodium sesquihydrate (PSS) is a proton pump inhibitor, used in acid-related
disorders, like peptic ulcer and gastroesophageal reﬂux. Increasing the number of pantoprazole con-
taining products in the market, raises questions of its efﬁcacy and generic substitution. The pharma-
ceutical quality of 6 generic PSS enteric coated tablets in 2 local markets was assessed relative to the
innovator product (pantozol). Uniformity of dosage unit, disintegration and in vitro drug release
were determined using United States pharmacopeia for delayed release tablets. The similarity factor
(f2)was assessed using theFDArecommended approach (f2 similarity factor). The content uniformity
of the innovator product was 98.39%of the labeled claimwithRSD value of 1.08%, while the content
of generic products ranged from 96.98% to 98.80%with RSD values of 1.24–2.19%. All the products
showed no disintegration, cracks or swelling in 0.1 N HCl, except product 1, which showed complete
disintegration after 20 min. However, the disintegration of all the products in phosphate buffer met
USP requirements. Dissolution of tablets in 0.1 N HCl showed no drug release after 2 h except prod-
uct 1 inwhich one tablet showed a drug releasemore than 10%at acid stage levelA1. In addition, three
tablets of this product showed dissolution of 45%, 48% and 69% at acid stage level A2. The similarity
factor f2 of the products was between 71 and 74 indicating the similarity in dissolution proﬁles of all
the products in accordance to FDA requirements, except product 1 in which f2 value was 18.67.
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lsevier1. Introduction
A generic drug is identical, or bioequivalent to a brand name
drug in dosage form, safety, strength, route of administration,
quality, performance characteristics and intended use.
Although generic drugs are chemically identical to their
branded counterparts, they are typically sold at substantial dis-
counts from the branded price (Ofﬁce of Generic Drugs, 2009).
Drug companies must submit an abbreviated new drug appli-
cation (ANDA) for approval to market a generic product. The
ANDA process does not require the drug sponsor to repeat
124 H.F. Mostafa et al.costly animal and clinical research on ingredients or dosage
forms already approved for safety and effectiveness (Ofﬁce
of Generic Drugs, 2009). To gain FDA approval, a generic
drug must: contain the same active ingredients as the innova-
tor drug, be identical in strength, dosage form, and route of
administration, have the same use indications, be bioequiva-
lent, meet the same batch requirements for identity, strength,
purity, and quality and be manufactured under the same strict
standards of FDA’s good manufacturing practice regulations
required for innovator products (Dighe, 1999; Meyer, 1999).
As deﬁned in the USP, delayed-release drug products are
dosage forms that release the drugs at a time later than imme-
diately after administration (i.e., these drug products exhibit a
lag time in quantiﬁable plasma concentrations). Typically,
coatings (e.g., enteric coatings) are intended to delay the re-
lease of medication until the dosage form has passed through
the acidic medium of the stomach (United States Pharmaco-
peia & National Formulary, 2004). A major aim of enteric
coating is the protection of drugs that are sensitive or unstable
at acidic pH (Liu et al., 2009; Brogmann and Beckert, 2001).
This is particularly important for drugs such as enzymes (Kel-
ler et al., 2009) and proteins (Brogmann and Beckert, 2001),
because these macromolecules are rapidly hydrolyzed and
inactivated in acidic medium. Antibiotics are also rapidly de-
graded by gastric juices (Skinner et al., 1993; Bersanetti
et al., 2005). Others, such as acidic drugs like NSAID’s (e.g.,
diclofenac, valproic acid, or acetylsalicylic acid) need to be en-
teric coated to prevent local irritation of the stomach mucosa
(Todd and Sorkin, 1988).
Pantoprazole, 5-(diﬂuoromethoxy)-2-[(3,4-dimethoxypyri-
din-2-yl)methylsulﬁnyl]-3H-benzoimidazole, is a substituted
benzimidazole derivative that inhibits gastric acid secretion
by irreversibly binding the proton pump (H+/K+-ATPase)
in the gastric parietal cells (Jungnickel, 2000). It is used for
the treatment of gastrointestinal conditions particularly peptic
ulceration, Zollinger–Ellison syndrome and reﬂux esophagitis
(Cheer et al., 2003) and it is also very effective against Helico-
bacter pylori infections alone or associated to other drugs, like
metronidazole, clarithromycin or amoxicillin (Cheer et al.,
2003; Poole, 2001). Pantoprazole is unstable at low pH values.
The highest stability of this drug is achieved at a pH value
higher than 5.5. Therefore, Pantoprazole is commercially for-
mulated as enteric coated tablets or capsules (Badwan et al.,
2002).
The aim of this work was to compare the enteric efﬁcacy of
six generic products of coated pantoprazole sodium sesquihy-
drate Tablets in 2 local markets with the innovator product,
and to evaluate these products according to United States
pharmacopeia and food and drug administration guidelines.2. Materials and methods
2.1. Materials
Tribasic sodium phosphate and Sodium hydroxide were pur-
chased from E. Merck AB, Stockholm, Sweden. Hydrochloric
acid 37% was supplied by BDH Laboratory Supplies, Eng-
land. The innovator product (pantozol (20.0 mg pantopraz-
ole), Altana, Germany) and 6 generic pantoprazole sodium
sesquihydrate enteric coated tablets were purchased from 2 lo-
cal markets.2.2. Methods
2.2.1. Tablet weight variation
Twenty tablets from each product were individually weighed
on an analytical balance (Mettler, Switzerland). The average
weight and relative standard deviation were reported.
2.2.2. Tablet thickness
The thickness was measured individually for 10 preweighed
tablets by using a portable dial hand micrometer (Starrett,
USA). The average, standard deviation and relative standard
variation were reported.
2.2.3. Uniformity of dosage unit
Pantoprazole content was assessed according to the USP 27
requirements for content uniformity. Pantoprazole tablets
were examined using UV Spectrophotometer (Labomed, Inc,
USA), wavelength 295 nm. Individual tablets were placed in
100 ml volumetric ﬂask and 70 ml of 0.1 N NaOH was added
and the dispersion was sonicated to dissolve the tablet and
then the volume was completed to 100 ml with 0.1 N NaOH.
Five ml of the previously mentioned solution was placed in a
100 ml volumetric ﬂask and the volume was completed with
the same solvent.
2.2.4. Tablet disintegration
Disintegration of tablets was performed according to USP 27
‘‘Disintegration Test’’ for delayed release dosage forms using
a disintegration tester (Electrolab, India). A minimum of 6
tablets of each product were tested. One tablet of each product
was placed in each of the six tubes of the basket. Then the
apparatus was operated using 1 l of 0.1 N HCl maintained at
37 ± 2 C for 1 h and using 1 l of 0.05 M phosphate buffer,
pH 6.8, maintained at 37 ± 2 C, for 30 min.
2.2.5. In vitro release studies
In vitro drug release was performed for the tablets according
to the USP 27 ‘‘Dissolution procedure’’ for delayed release
dosage forms. A minimum of 6 tablets of each product were
tested. The dissolution of pantoprazole from the enteric coated
tablets was monitored using an automated dissolution tester
(LOGAN Instrument Corp, Somerset, NJ, USA) coupled to
an automated sample collector (SP-100 peristaltic pump, Som-
erset, NJ, USA). The USP 27 (apparatus 2) paddle method was
used at 75 rpm. The media used was 0.1 N HCl at a pH 1.2 and
a volume of 750 ml for the ﬁrst 2 h after which 250 ml of 0.2 M
sodium phosphate, tribasic, was added to give a ﬁnal pH of 6.8
and maintained at 37 ± 0.5 C.
Pantoprazole release from each tablet (in the dissolution
samples) was determined by UV spectrophotometer (UV-
1800, Shimadzu, Tyoto, Japan) at WV 290 nm. Dissolution
proﬁles for each product were compared to the innovator to
determine the enteric coating efﬁcacy of the generic products.
The dissolution similarity was assessed using the FDA recom-
mended approach (f2 similarity factor). The similarity factor is
a logarithmic, reciprocal square root transformation of the
sum of squared errors, and it serves as a measure of the simi-
larity of two respective dissolution proﬁles:
f2 ¼ 50 logf½1þ 1=n
Xn
t¼1
ðRT TtÞ2 ¼ 0:5:100g
Table 2 Disintegration of pantoprazole enteric coated tablets
in 0.1 N HCl (pH 1.2) and 0.05 M phosphate buffer (pH 6.8).
Product Disintegration time
at 0.1 N HCl (min)
Disintegration
time at 0.05 M
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marketed product release proﬁle and Tt is the percent of test
formulations release observed. FDA has set a public standard
of the f2 value between 50 and 100 to indicate similarity
between two dissolution proﬁles (FDA, 1997).
phosphate
buﬀer (min)
Innovator No disintegration after
60 min
8.0
Generic product 1 20 7.0
Generic product 2 No disintegration after
60 min
9.5
Generic product 3 No disintegration after
60 min
8.5
Generic product 4 No disintegration after
60 min
7.5
Generic product 5 No disintegration after
60 min
8.5
Generic product 6 No disintegration after
60 min
7.53. Results
3.1. Weight variation and tablet thickness
The results of weight and thickness parameters are expressed
as mean and relative standard deviation in (Table 1). All prod-
ucts showed different average weights that ranged from 84 to
211 mg, which indicates the use of different excipients with dif-
ferent weights.
3.2. Content uniformity
Pantoprazole sodium sesquihydrate enteric coated tablets con-
tent uniformity was calculated, the percentages of the drug
were within the USP limit (85–115% of the theoretical label
claim (22.6 mg/tablet)) with relative standard deviations of less
than 2.5% (Table 1). The content uniformity of the innovator
product was 98.39% of the labeled claim with RSD value of
1.08%, while the content of generic products ranged from
96.98% to 98.80% with RSD values of 1.24–2.19%.
3.3. Tablet disintegration
All the tested products showed no evidence of disintegration,
cracks or swelling in 0.1 N HCl, except generic product 1,
which showed complete disintegration of all the tablets after
20 min, which indicates inappropriate enteric coating of the
tablets. However, the disintegration of all the products in
phosphate buffer (pH 6.8) met USP requirements (Table 2).
3.4. In vitro release studies
Tablet dissolution in 0.1 N HCl exhibited no drug release after
2 h except the generic product 1, in which only one tablet re-
leased more than 10% of the drug at acid stage level A1. In
addition, three tablets of this product gave a dissolution great-
er than 25% (45%, 48%, and 69%) and the average of 12 tab-
lets released more than 10% at acid stage level A2. All other
generic products were complying with the USP dissolution test
as shown in (Fig. 1).
The similarity factor (f2) of the products was between 71
and 74 indicating the similarity in dissolution proﬁles of allTable 1 Weight variation, tablet thickness and content uniformity
Product Weight (mg) ±SD T
Innovator 103.3 ± 3.093 3
Generic product 1 211.8 ± 3.915 3
Generic product 2 101.8 ± 1.687 3
Generic product 3 84.10 ± 1.197 3
Generic product 4 92.45 ± 0.94 3
Generic product 5 152.0 ± 1.76 3
Generic product 6 183.2 ± 2.38 3the products in accordance to FDA requirements, except the
non-complying generic product 1, in which the f2 value was
18.67 (Fig. 2).
4. Discussion
Pantoprazole sodium sesquihydrate enteric coated tablets are
marketed in various brand names as generic drugs. Thus, the
efﬁcacy of generic drugs should be assessed compared with
the innovator in order to know the difference in effect between
them. Generic drugs should be formulated to have a similar ef-
fect as an innovator drug.
Pantoprazole sodium sesquihydrate is highly unstable at
low pH values, so, it is formulated as enteric coated tablets
or capsules. Any defect in the enteric coat will result in the re-
lease of the drug in acidic medium, which leads to degradation
of the liberated amount of drug. The defect may be due to
choosing the coating material, concentration of the coating
material, type of solvent and/or curing time.
By Physical examination of the generic product1, a non-
homogenous enteric coat was observed, which indicate a prob-
lem in the coating. As shown in the results, generic product 1
showed release of drug in acidic medium and failed to reach
100% (less than 60%) in buffer medium, which indicates drug
degradation in acid medium. This will lead to decreased efﬁ-
cacy of pantoprazole enteric coated tablet due to the degraded
amount released in acidic medium.
So, it is strongly recommended to assess the performance of
drug products postmarketing and for strengthening the role ofof pantoprazole enteric coated tablets.
hickness (mm) ±SD Content uniformity (%) ±SD
.27 ± 0.045 98.39 ± 1.07
.59 ± 0.032 96.98 ± 2.13
.06 ± 0.034 97.91 ± 1.7
.01 ± 0.016 98.46 ± 1.22
.11 ± 0.02 97.46 ± 1.38
.56 ± 0.02 98.22 ± 1.51
.51 ± 0.05 98.8 ± 1.42
Figure 1 Dissolution proﬁles of pantoprazole enteric coated tablets.
Figure 2 Similarity factor (f2) of pantoprazole enteric coated
tablets.
126 H.F. Mostafa et al.the national regulatory system to ensur the quality of multi-
source products.
5. Conclusion
The results obtained from this comparative study concluded
that there was a similarity between the innovator and the gen-
eric products except generic product 1, which showed a signif-
icant variation in the in vitro release pattern compared with
the innovator. This generic product failed to pass USP require-
ments for delayed release tablets and didn’t comply with FDA
guidelines for generic products. This is due to inappropriate
coating which resulted in the release of the drug in acid med-
ium, which indicates non-effective product. Thus, stricter con-
trol of the marketed products must be implemented by local
regulatory authorities.Acknowledgment
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